Polygenic Risk Scores Accurately Predict Risk of Coronary Artery Disease
By LabMedica International staff writers Posted on 24 Jun 2019 |
Image: A micrograph of a coronary artery with the most common form of coronary artery disease (atherosclerosis) and marked luminal narrowing (Photo courtesy of Wikimedia Commons).
Polygenic risk scores (PRS) based on an individual's genome sequence are emerging as potentially powerful biomarkers to predict the risk to develop coronary artery disease (CAD).
Previous studies have shown that PRSs were able to predict CAD risk with high accuracy in people of European ancestry. In the current work, investigators at the University of Montreal (Canada) looked at how well such results would translate to a different population, in this case French Canadians.
The investigators calculated PRS in French-Canadian individuals from three cohorts totaling 3639 prevalent CAD cases and 7382 controls, and tested their power to predict prevalent, incident, and recurrent CAD. They also estimated the impact of the founder French-Canadian familial hypercholesterolemia mutation on individuals suffering from this genetic disorder.
Results confirmed the ability of PRS to predict prevalent CAD comparable to the original reports. Furthermore, the PRS identified about 6-7% of individuals at CAD risk similar to carriers of the hypercholesterolemia mutation. However, the PRS did not perform as well in predicting incident or recurrent CAD, perhaps due to the fact that 76% of the participants were on statin treatment.
"PRSs, built using very large data sets of people with and without heart disease, look for genetic changes in the DNA that influence disease risk, whereas individual genes might have only a small effect on disease predisposition," said senior author Dr. Guillaume Lettre, associate professor of medicine at the University of Montreal. "The PRS is like having a snapshot of the whole genetic variation found in one's DNA and can more powerfully predict one's disease risk. Using the score, we can better understand whether someone is at higher or lower risk to develop a heart problem."
The American Heart Association (Dallas, TX, USA) named the use of polygenic risk scores as one of the biggest advances in heart disease and stroke research in 2018.
"Eventually, clinicians could use polygenic risk scores along with family history, cholesterol, and blood pressure to determine heart disease risk. Used early in a person's life it might help clinicians more precisely tailor treatment aimed at preventing a heart attack in later years," said Dr. Jennifer Hall, chief of the institute for precision medicine of the American Heart Association.
The French Canadian PRS paper was published in the June 11, 2019, online edition of the journal Circulation: Genomic and Precision Medicine.
Related Links:
University of Montreal
American Heart Association
Previous studies have shown that PRSs were able to predict CAD risk with high accuracy in people of European ancestry. In the current work, investigators at the University of Montreal (Canada) looked at how well such results would translate to a different population, in this case French Canadians.
The investigators calculated PRS in French-Canadian individuals from three cohorts totaling 3639 prevalent CAD cases and 7382 controls, and tested their power to predict prevalent, incident, and recurrent CAD. They also estimated the impact of the founder French-Canadian familial hypercholesterolemia mutation on individuals suffering from this genetic disorder.
Results confirmed the ability of PRS to predict prevalent CAD comparable to the original reports. Furthermore, the PRS identified about 6-7% of individuals at CAD risk similar to carriers of the hypercholesterolemia mutation. However, the PRS did not perform as well in predicting incident or recurrent CAD, perhaps due to the fact that 76% of the participants were on statin treatment.
"PRSs, built using very large data sets of people with and without heart disease, look for genetic changes in the DNA that influence disease risk, whereas individual genes might have only a small effect on disease predisposition," said senior author Dr. Guillaume Lettre, associate professor of medicine at the University of Montreal. "The PRS is like having a snapshot of the whole genetic variation found in one's DNA and can more powerfully predict one's disease risk. Using the score, we can better understand whether someone is at higher or lower risk to develop a heart problem."
The American Heart Association (Dallas, TX, USA) named the use of polygenic risk scores as one of the biggest advances in heart disease and stroke research in 2018.
"Eventually, clinicians could use polygenic risk scores along with family history, cholesterol, and blood pressure to determine heart disease risk. Used early in a person's life it might help clinicians more precisely tailor treatment aimed at preventing a heart attack in later years," said Dr. Jennifer Hall, chief of the institute for precision medicine of the American Heart Association.
The French Canadian PRS paper was published in the June 11, 2019, online edition of the journal Circulation: Genomic and Precision Medicine.
Related Links:
University of Montreal
American Heart Association
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples